[{“box”:0,”content”:”n[if 992 equals=”Open Access”]n
n
Open Access
nn
n
n[/if 992]n[if 2704 equals=”Yes”]n
nThis is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.n
n[/if 2704]n
n
n
nn
n
Gaurang Rai,
n t
n
n[/foreach]
n
n[if 2099 not_equal=”Yes”]n
- [foreach 286] [if 1175 not_equal=””]n t
- Student, Department of Computer Science and Engineering (CSE), VIT Bhopal University, Madhya Pradesh, India
n[/if 1175][/foreach]
n[/if 2099][if 2099 equals=”Yes”][/if 2099]n
Abstract
n
n
nThe application of artificial intelligence (AI) in medicine, specially through machine learning (ML), is revolutionizing new age drug discovery research. AI is found as a efficient and powerful tool to narrow the gap between disease detection and the developing and identifying potential therapeutic agents for cure. This review describes brief summary of the latest developments in AI and its potential application in drug discovery for untreatable diseesas. Review also examines the various basic stages of the drug discovery process, like a) disease identification and b) disease proper diagnosis, c) target identification, d) screening, and e) drug discovery. AI’s application will greatly help to analyse huge datasets and discern patterns which is very essential in these early stages of drug discovery. Thus, enhancing accurate predictions and efficiencies in disease identification and most suitable drug discovery, followed by clinical trial management. In this review, the role of AI in expediting drug development work is highlighted its great potential to analyse huge historical data volumes, which will significantly reduce the time and costs required for new drug development and its market introduction. The need of data quality, algorithm training, and ethical considerations, especially in patient data handling during clinical trials during drug discovery development work using AI, is emphasised. Considering above mentioned factors, AI seems to be capable of transforming drug development and assures significant benefits to patients and society globally- a great support to humanitynn
n
Keywords: Artificial intelligence, Machine learning, Disease identification, Drug design, Drug discovery.
n[if 424 equals=”Regular Issue”][This article belongs to Emerging Trends in Chemical Engineering ]
n
n
n
n
nGaurang Rai. [if 2584 equals=”][226 wpautop=0 striphtml=1][else]Application of Artificial Intelligence in Drug Discovery”[/if 2584]. Emerging Trends in Chemical Engineering. 17/09/2025; 12(03):-.
n
nGaurang Rai. [if 2584 equals=”][226 striphtml=1][else]Application of Artificial Intelligence in Drug Discovery”[/if 2584]. Emerging Trends in Chemical Engineering. 17/09/2025; 12(03):-. Available from: https://journals.stmjournals.com/etce/article=17/09/2025/view=0
nn
n
n[if 992 not_equal=”Open Access”]n
n
n[/if 992]n
nn
Browse Figures
n
n
n[/if 379]
n
n
n
References n
n[if 1104 equals=””]n
- Vamathevan, J., Clark, D., Czodrowski, P., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477.
- Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9), 1038–1040.
- Jumper, J., Evans, R., Pritzel, A., et al. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583–589.
- Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. Drug Discovery Today, 23(6), 1241–1250.
- V. Hinkson, B. Madej, E.A. Stahlberg Accelerating therapeutics for opportunities in medicine: A paradigm shift in drug discovery Front. Pharmacol., 11 (2020), p. 770
- Barker A flexible blueprint for the future of drug development Lancet, 375 (2010), pp. 357-359
- Sun, W. Gao, H. Hu, et al. Why 90% of clinical drug development fails and how to improve it? Acta. Pharm. Sin. B, 12 (2022), pp. 3049-3062
- Hassanzadeh, F. Atyabi, R. Dinarvand The significance of artificial intelligence in drug delivery system design Adv. Drug Deliv. Rev., 151-152 (2019), pp. 169-190
- D. Bolcer, R.B. Hermann The development of computational chemistry in the United States Rev. Comput. Chem. (1994), pp. 1-63
- Bianconi, M. Filippucci Digital Wood Design: Innovative Techniques of Representation in Architectural Design Springer (2019) Vol. 24
- Ding, J.H. Sohn, M.G. Kawczynski, et al. A deep learning model to predict a diagnosis of Alzheimer disease by using 18F-FDG PET of the brain Radiology, 290 (2019), pp. 456-464
- Narin, C. Kaya, Z. Pamuk Automatic detection of coronavirus disease (covid-19) using x-ray images and deep convolutional neural networks Pattern Anal. Appl., 24 (2021), pp. 1207-1220
- Gentile, J.C. Yaacoub, J. Gleave, et al. Artificial intelligence–enabled virtual screening of ultra-large chemical libraries with deep docking Nat. Protoc., 17 (2022), pp. 672-697
- A. Carpenter, D.S. Cohen, J.T. Jarrell, et al. Deep learning and virtual drug screening Future Med. Chem., 10 (2018), pp. 2557-2567
- Bule, N. Jalalimanesh, Z. Bayrami, et al. The rise of deep learning and transformations in bioactivity prediction power of molecular modeling tools Chem. Biol. Drug Des., 98 (2021), pp. 954-967
- Berzuini, R. Bellazzi, S. Quaglini, et al .Bayesian networks for patient monitoring Artif. Intell. Med., 4 (1992), pp. 243-260
- Kapsiani, B.J. Howlin Random forest classification for predicting lifespan-extending chemical compounds Sci. Rep., 11 (2021), pp. 1-13
- Heikamp, J. Bajorath Support vector machines for drug discovery Expert Opin. Drug Discov., 9 (2014), pp. 93-104
- Paul D., Sanap G., Shenoy S., Kalyane D., Kalia K., Tekade R.K. Artificial intelligence in drug discovery and development. Drug Discov. Today. 2021;26:80–93. doi: 10.1016/j.drudis.2020.10.010
- Xu Y., Liu X., Cao X., Huang C., Liu E., Qian S., Liu X., Wu Y., Dong F., Qiu C.W., et al. Artificial intelligence: A powerful paradigm for scientific research. Innovation. 2021;2:100179. doi: 10.1016/j.xinn.2021.100179.
- Zhuang D., Ibrahim A.K. Deep learning for drug discovery: A study of identifying high efficacy drug compounds using a cascade transfer learning approach. Appl. Sci. 2021;11:7772. doi: 10.3390/app11177772
- Pu L., Naderi M., Liu T., Wu H.C., Mukhopadhyay S., Brylinski M. EToxPred: A machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacol. Toxicol. 2019;20:2. doi: 10.1186/s40360-018-0282-6.
- Rees C. IFIP Advances in Information and Communication Technology. 1st ed. Volume 555. CRC Press/Taylor & Francis Group; Boca Raton, FL, USA: 2020. The Ethics of Artificial Intelligence; pp. 55–69. Chapman and Hall/CRC.
- Abou Hajal A, Al Meslamani AZ. Insights into artificial intelligence utilisation in drug discovery. J Med Econ. 2024;27(1):304–8.
- Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1(9):727–30.
- Lin Q, Tam PK-H, Tang CS-M. Artificial intelligence-based approaches for the detection and prioritization of genomic mutations in congenital surgical diseases. Front Pediatr. 2023;11:1203289.
- Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–6.
- Knox C, et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52(D1):1265-d1275.
- Kim S, et al. PubChem 2025 update. Nucleic Acids Res. 2024;53(D1):D1516–25.
- Lv J, et al. ACDB: an antibiotic combination database. Front Pharmacol. 2022;13:869983.
- Lv J, et al. AADB: a manually collected database for combinations of antibiotics with adjuvants. IEEE/ACM Trans Comput Biol Bioinf. 2023;20(5):2827–36.
- Chen W, et al. Artificial intelligence for drug discovery: resources, methods, and applications. Mol Ther Nucleic Acids. 2023;31:691–702.
- Qiu X, et al. Advances in AI for protein structure prediction: implications for cancer drug discovery and development. Biomolecules. 2024;14(3):339.
- Serrano DR, et al. Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. Pharmaceutics. 2024;16(10):1328.
- Osama S, Shaban H, Ali AA. Gene reduction and machine learning algorithms for cancer classification based on microarray gene expression data: a comprehensive review. Expert Syst Appl. 2023;213:118946.
- Statnikov A, et al. A comprehensive evaluation of multicategory classification methods for microarray gene expression cancer diagnosis. Bioinformatics. 2005;21(5):631–43.
- Friedman J. The elements of statistical learning: data mining, inference, and prediction.(No Title), 2009
- Ching T, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15(141):20170387.
- Boby ML, et al. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science. 2023;382(6671):201.
- Shen M-Y, et al. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets. Chem Res Toxicol. 2011;24(6):934–49.
- Hassanzadeh P. The significance of artificial intelligence in drug delivery system design. Adv. Drug Delivery Rev. 2019;151:169–190. doi: 10.1016/j.addr.2019.05.001
- Luo M. Micro‐/nanorobots at work in active drug delivery. Adv. Funct. Mater. 2018;28:1706100
- Fu J., Yan H. Controlled drug release by a nanorobot. Nat. Biotechnol. 2012;30:407–408. doi: 10.1038/nbt.2206
- Calzolari D. Search algorithms as a framework for the optimization of drug combinations. PLoS Comput. Biol. 2008;4:e1000249. doi: 10.1371/journal.pcbi.1000249.
- Wilson B., KM G. Artificial intelligence and related technologies enabled nanomedicine for advanced cancer treatment. Future Med. 2020;15:433–435. doi: 10.2217/nnm-2019-0366
- Tsigelny I.F. Artificial intelligence in drug combination therapy. Brief. Bioinform. 2019;20:1434–1448. doi: 10.1093/bib/bby004
- A Phase 1 Breakthrough in AI Drug Discovery, https://insilico.com/blog/ipf-phase1#:~:text=The%20safety%20and%20PK%20data,in%20drug%20discovery%20and%20development.
- AlphaFold Protein Structure Database, https://alphafold.ebi.ac.uk/
- BenevolentAI · AI-Enabled Drug Discovery, https://www.benevolent.com/news-and-media/blog-and-videos/benevolentai-ai-enabled-drug-discovery/
- The Potential of AI in Drug Discovery and its Impact on Healthcare, https://appinventiv.com/blog/ai-in-drug-discovery/
- Unleashing AI in Drug Discovery: Prospects and Challenges, https://blog.drugbank.com/unleashing-ai-in-drug-discovery-prospects-and-challenges/
nn[/if 1104][if 1104 not_equal=””]n
- [foreach 1102]n t
- [if 1106 equals=””], [/if 1106][if 1106 not_equal=””],[/if 1106]
n[/foreach]
n[/if 1104]
n
nn[if 1114 equals=”Yes”]n
n[/if 1114]
n
n
n
nn
n
| Volume | 12 | |
| [if 424 equals=”Regular Issue”]Issue[/if 424][if 424 equals=”Special Issue”]Special Issue[/if 424] [if 424 equals=”Conference”][/if 424] | 03 | |
| Received | 20/07/2025 | |
| Accepted | 31/08/2025 | |
| Published | 17/09/2025 | |
| Retracted | ||
| Publication Time | 59 Days |
n
n
nn
n
Login
PlumX Metrics
n
n
n[if 1746 equals=”Retracted”]n
[/if 1746]nnn
nnn”}]
